



Date: February 7, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Wednesday, February 7, 2024, inter-alia has:

1. Considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023.
2. Approved the Capital Expenditure plan at Ambernath site for CDMO facility.

The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 03:15 p.m. and concluded at 05:20 p.m.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



SUPRIYA LIFESCIENCE LIMITED
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months ended 31st December, 2023

(₹ in million)

| Sr.No. | Particulars | Quarter ended | Quarter ended | Quarter ended | Nine Months ended | Nine Months ended | Year ended |
|--------|---|-----------------|-----------------|-----------------|-------------------|-------------------|-----------------|
| | | 31-12-2023 | 30-09-2023 | 31-12-2022 | 31-12-2023 | 31-12-2022 | 31-03-2023 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I | Revenue from Operations | 1,400.74 | 1,400.95 | 1,051.40 | 4,121.89 | 3,186.67 | 4,609.38 |
| II | Other Income | 30.65 | 24.67 | 25.64 | 84.50 | 75.25 | 94.89 |
| III | Total Income | 1,431.39 | 1,425.62 | 1,077.03 | 4,206.39 | 3,261.92 | 4,704.27 |
| 2 | Expenses | | | | | | |
| | a) Cost of Materials Consumed | 448.43 | 507.03 | 547.19 | 1,430.74 | 1,397.95 | 1,873.18 |
| | b) Purchase of Stock in Trade | - | - | - | - | - | - |
| | c) Change in inventories of finished goods, work in progress & stock in trade. | 97.78 | 109.36 | (33.71) | 204.06 | (65.45) | (65.06) |
| | d. Employee benefit expenses | 175.64 | 175.02 | 146.45 | 504.94 | 402.75 | 555.78 |
| | e. Finance Cost | 4.94 | 4.60 | 10.14 | 15.09 | 23.73 | 30.84 |
| | f. Depreciation & amortisation expense | 39.60 | 39.81 | 29.50 | 118.97 | 88.08 | 118.15 |
| | g. Other expenditure | 264.00 | 292.02 | 251.03 | 807.44 | 712.88 | 956.49 |
| IV | Total Expenses | 1,030.39 | 1,127.84 | 950.60 | 3,081.24 | 2,559.94 | 3,469.40 |
| V | Profit/(loss) before Exceptional Items & Tax (III -IV) | 400.99 | 297.78 | 126.43 | 1,125.15 | 701.98 | 1,234.87 |
| VI | Exceptional Items | - | - | - | - | - | - |
| VII | Profit/(Loss) before Tax (V-VI) | 400.99 | 297.78 | 126.43 | 1,125.15 | 701.98 | 1,234.87 |
| VIII | Tax Expense | | | | | | |
| | a) Current Tax | 96.55 | 85.38 | 24.21 | 281.56 | 174.74 | 306.81 |
| | b) Deferred Tax | 6.57 | (26.44) | 7.05 | 21.77 | 10.96 | 29.49 |
| | c) Income Tax for Earlier Years | - | - | - | - | - | - |
| IX | Profit/(Loss) for the period from Continuing Operations (VII-VII) | 297.87 | 238.84 | 95.18 | 821.82 | 516.28 | 898.57 |
| X | Profit/(Loss) from discontinued operations before tax | - | - | - | - | - | - |
| XI | Tax Expense of discontinued operations | - | - | - | - | - | - |
| XII | Profit/(Loss) from discontinued operations after tax (X-XI) | - | - | - | - | - | - |
| XIII | Profit/(Loss) for the period (IX+XII) | 297.87 | 238.84 | 95.18 | 821.82 | 516.28 | 898.57 |
| XIV | Other Comprehensive Income | | | | | | |
| | A (i) Items that will not be reclassified to profit or loss | 3.61 | (1.84) | (0.34) | 21.23 | (10.59) | (16.80) |
| | (ii) Income Tax relating to items that will not be reclassified to profit or loss | (0.91) | 0.46 | 0.09 | (5.34) | 2.66 | 4.23 |
| | B (i) Items that will be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income Tax relating to items that will be reclassified to profit or loss | - | - | - | - | - | - |
| XV | Total Comprehensive Income for the period (XIII+XIV) | 300.57 | 237.46 | 94.92 | 837.71 | 508.36 | 886.00 |
| XVI | Earnings per equity Share (for continuing operation): | | | | | | |
| | (1) Basic (In ₹) | 3.70 | 2.97 | 1.18 | 10.21 | 6.41 | 11.16 |
| | (2) Diluted (In ₹) | 3.70 | 2.97 | 1.18 | 10.21 | 6.41 | 11.16 |
| XVII | Earnings per equity Share (for discontinued operation): | | | | | | |
| | (1) Basic (In ₹) | - | - | - | - | - | - |
| | (2) Diluted (In ₹) | - | - | - | - | - | - |
| XVIII | Earnings per equity Share (for discontinued & continuing operations): | | | | | | |
| | (1) Basic (In ₹) | 3.70 | 2.97 | 1.18 | 10.21 | 6.41 | 11.16 |
| | (2) Diluted (In ₹) | 3.70 | 2.97 | 1.18 | 10.21 | 6.41 | 11.16 |

See accompanying notes to the financial statements:

Notes:-

- The Unaudited Standalone financial results of the Company for the quarter & nine months ended 31st December, 2023 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
- The above Unaudited standalone financial results of the Company for the quarter & nine months ended 31st December, 2023 have been reviewed by the Audit Committee on 07th February, 2024 and thereafter approved by the Board of Directors at their meeting held on 07th February, 2024.
- The Company has adopted Ind AS 116 "Leases" effective 01st April, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. 01st April, 2019.
- The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
- The standalone financial results include the results for the quarter ended 31st December 2023 being the balancing figure between the Unaudited figures in respect of the Nine months ended 31st December, 2023 and the published unaudited half year figures up to the second quarter of the current financial year which were subject to limited review by us.

For and on behalf of The Board of directors of
Supriya Lifescience Ltd.



Dr. Satish Waman Wagh
Chairman & Managing Director
DIN: 01456982

PLACE :- MUMBAI
DATE :- 07-02-2024

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF.:

OUR REF.:

Independent Auditor's Limited Review Report on Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of Supriya Lifescience Limited ("the Company") for the quarter & nine months ended December 31, 2023, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on February 07, 2024, has been compiled from the related IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,
Mumbai - 400 053 Tel: 022 26744670. Email: mumbai.kakaria@gmail.com ,
Website: www.kakariaassociates.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai
Date: - 07th February, 2024
UDIN: - 24035416BK6ORK2227



Date: February 7, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Approval of Capital Expenditure at Ambernath site for CDMO facility

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that Supriya Lifescience Limited is planning a capex program at Ambernath site with an estimated aggregate capital outlay of Rs. 60 crores over the next 3 years.

The Board of Directors, at their meeting held today has initially approved capital expenditure of approx. Rs. 60 crores for site development and related infrastructure on approx. 5000 sq mtr. of land for project at Ambernath. The said capital expenditure would be majorly funded by the Company out of its internal accruals.

The development of this factory will enable the Company to set up facility required for various CDMO projects.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com